The increase in weight loss with the higher dose was impressive, but still lower than has been achieved in clinical trials of Eli Lilly's rival obesity therapy Zepbound (tirzepatide), which helped ...
A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with competitor Eli Lilly’s Zepbound.
Eli Lilly has launched new single-dose 2.5mg and 5.0mg vials of its obesity drug Zepbound in a move that it said would make it easier for people paying for the drug out-of-pocket to afford treatment.
Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.
Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...